Item Type | Name |
Concept
|
Antineoplastic Agents
|
Concept
|
Antineoplastic Agents, Hormonal
|
Concept
|
Antineoplastic Agents, Phytogenic
|
Academic Article
|
Phase I study of amonafide dosing based on acetylator phenotype.
|
Academic Article
|
Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents.
|
Academic Article
|
Phase I clinical and pharmacology study of 502U83 given as a 24-h continuous intravenous infusion.
|
Academic Article
|
Modulation of glucuronidation of SN-38, the active metabolite of irinotecan, by valproic acid and phenobarbital.
|
Academic Article
|
Interleukin-2 fusion protein: an investigational therapy for interleukin-2 receptor expressing malignancies.
|
Academic Article
|
Phase I study of suramin administered by intermittent infusion without adaptive control to cancer patients: update of two expanded dose levels near the maximally tolerated dose.
|
Academic Article
|
Dose-escalation trial of cladribine using five daily intravenous infusions in patients with advanced hematologic malignancies.
|
Academic Article
|
Keratoacanthomas and skin neoplasms associated with suramin therapy.
|
Academic Article
|
Mineralocorticoid insufficiency due to suramin therapy.
|
Academic Article
|
Pharmacodynamic modeling of prolonged administration of etoposide.
|
Academic Article
|
Limited-sampling models for irinotecan pharmacokinetics-pharmacodynamics: prediction of biliary index and intestinal toxicity.
|
Academic Article
|
Data modifications to phase I study of suramin.
|
Academic Article
|
Individualized dosing of amonafide based on a pharmacodynamic model incorporating acetylator phenotype and gender.
|
Academic Article
|
Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients.
|
Academic Article
|
Study of cohort-specific consent and patient control in phase I cancer trials.
|
Academic Article
|
A phase II study of 9-aminocamptothecin in advanced non-small-cell lung cancer.
|
Academic Article
|
Phase I clinical and pharmacokinetic study of oral 9-aminocamptothecin (NSC-603071).
|
Academic Article
|
Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2.
|
Academic Article
|
Promising new agents in oncologic treatment.
|
Academic Article
|
Oral chemotherapy: rationale and future directions.
|
Academic Article
|
Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes.
|
Academic Article
|
Balanced translocations involving chromosome bands 11q23 and 21q22 in therapy-related leukemia.
|
Academic Article
|
Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism.
|
Academic Article
|
O6-benzylguanine in humans: metabolic, pharmacokinetic, and pharmacodynamic findings.
|
Academic Article
|
Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264.
|
Academic Article
|
Phase I study of ZD9331 on short daily intravenous bolus infusion for 5 days every 3 weeks with fixed dosing recommendations.
|
Academic Article
|
Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer.
|
Academic Article
|
Clinical pharmacology of camptothecins.
|
Academic Article
|
Development of target-based antineoplastic agents.
|
Academic Article
|
Flavopiridol metabolism in cancer patients is associated with the occurrence of diarrhea.
|
Academic Article
|
Insights into the pharmacokinetics and pharmacodynamics of irinotecan.
|
Academic Article
|
Body-surface area as a basis for dosing of anticancer agents: science, myth, or habit?
|
Academic Article
|
Limited sampling model for area under the concentration time curve of total topotecan.
|
Academic Article
|
Pharmacogenetics and cancer chemotherapy.
|
Academic Article
|
Pharmacogenetics in cancer etiology and chemotherapy.
|
Academic Article
|
Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides.
|
Academic Article
|
Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development?
|
Academic Article
|
Dear doctor: we really are not sure what dose of capecitabine you should prescribe for your patient.
|
Academic Article
|
Estimation of the effect of food on the disposition of oral 5-fluorouracil in combination with eniluracil.
|
Academic Article
|
Irinotecan dosing: does the CPT in CPT-11 stand for "Can't Predict Toxicity"?
|
Academic Article
|
Update on pharmacogenetics in cancer chemotherapy.
|
Academic Article
|
UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity.
|
Academic Article
|
A phase I study of suramin with once- or twice-monthly dosing in patients with advanced cancer.
|
Academic Article
|
Elimination pathways of [14C]losoxantrone in four cancer patients.
|
Academic Article
|
Endostatin: are the 2 years up yet?
|
Academic Article
|
Pharmacogenetics: a tool for individualizing antineoplastic therapy.
|
Academic Article
|
Phase I clinical and pharmacogenetic study of weekly TAS-103 in patients with advanced cancer.
|
Academic Article
|
Pharmacogenetics of anticancer agents: lessons from amonafide and irinotecan.
|
Academic Article
|
Anticancer drug discovery and development throughout the world.
|
Academic Article
|
Troxacitabine in patients with refractory leukemia.
|
Academic Article
|
Determination of the optimal modulatory dose of O6-benzylguanine in patients with surgically resectable tumors.
|
Academic Article
|
Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480.
|
Academic Article
|
Pharmacogenetics in cancer treatment.
|
Academic Article
|
Population pharmacokinetic model for irinotecan and two of its metabolites, SN-38 and SN-38 glucuronide.
|
Academic Article
|
Biliary transport of irinotecan and metabolites in normal and P-glycoprotein-deficient mice.
|
Academic Article
|
In vitro characterization of hepatic flavopiridol metabolism using human liver microsomes and recombinant UGT enzymes.
|
Academic Article
|
Pharmacogenomics: road to anticancer therapeutics nirvana?
|
Academic Article
|
A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863.
|
Academic Article
|
Subcutaneously administered recombinant human interleukin-2 and interferon alfa-2a for advanced breast cancer: a phase II study of the Cancer and Leukemia Group B (CALGB 9041).
|
Academic Article
|
Relationship of baseline serum bilirubin to efficacy and toxicity of single-agent irinotecan in patients with metastatic colorectal cancer.
|
Academic Article
|
Clinical trial designs for cytostatic agents.
|
Academic Article
|
Paradoxical relationship between acetylator phenotype and amonafide toxicity.
|
Academic Article
|
Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors.
|
Academic Article
|
A phase I trial of pharmacokinetic modulation of carboxyamidotriazole (CAI) with ketoconazole in patients with advanced cancer.
|
Academic Article
|
A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors.
|
Academic Article
|
Dose-ranging study of the safety and pharmacokinetics of atrasentan in patients with refractory malignancies.
|
Academic Article
|
Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan.
|
Academic Article
|
Randomized discontinuation design: application to cytostatic antineoplastic agents.
|
Academic Article
|
Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B.
|
Academic Article
|
Irinotecan treatment in cancer patients with UGT1A1 polymorphisms.
|
Academic Article
|
Successful implementation of the randomized discontinuation trial design: an application to the study of the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma--CALGB 69901.
|
Academic Article
|
Modulation of irinotecan with cyclosporine: a phase II trial in advanced colorectal cancer.
|
Academic Article
|
Pharmacokinetic variability of anticancer agents.
|
Academic Article
|
Delivery of a liposomal c-raf-1 antisense oligonucleotide by weekly bolus dosing in patients with advanced solid tumors: a phase I study.
|
Academic Article
|
Pharmacokinetics, pharmacodynamics and adherence to oral topotecan in myelodysplastic syndromes: a Cancer and Leukemia Group B study.
|
Academic Article
|
A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871.
|
Academic Article
|
From bedside to bench to bedside to clinical practice: an odyssey with irinotecan.
|
Academic Article
|
Heritability and linkage analysis of sensitivity to cisplatin-induced cytotoxicity.
|
Academic Article
|
Finding the right dose.
|
Academic Article
|
Prospective evaluation of the relationship of patient age and paclitaxel clinical pharmacology: Cancer and Leukemia Group B (CALGB 9762).
|
Academic Article
|
Irinogenetics: what is the right star?
|
Academic Article
|
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma.
|
Academic Article
|
Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor.
|
Academic Article
|
Interpreting disparate responses to cancer therapy: the role of human population genetics.
|
Academic Article
|
Effects of green tea compounds on irinotecan metabolism.
|
Academic Article
|
Terminal ballistics of kinase inhibitors: there are no magic bullets.
|
Academic Article
|
The role of SN-38 exposure, UGT1A1*28 polymorphism, and baseline bilirubin level in predicting severe irinotecan toxicity.
|
Academic Article
|
A Phase II trial of suramin monthly x 3 for hormone-refractory prostate carcinoma.
|
Academic Article
|
Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST.
|
Academic Article
|
Biomarkers in early cancer drug development: limited utility.
|
Academic Article
|
Genome-wide identification of genetic determinants for the cytotoxicity of perifosine.
|
Academic Article
|
The Werner's syndrome 4330T>C (Cys1367Arg) gene variant does not affect the in vitro cytotoxicity of topoisomerase inhibitors and platinum compounds.
|
Academic Article
|
Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma.
|
Academic Article
|
Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301.
|
Academic Article
|
Etoposide pathway.
|
Academic Article
|
The cancer and leukemia group B pharmacology and experimental therapeutics committee: a historical perspective.
|
Academic Article
|
Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment.
|
Academic Article
|
Vascular endothelial growth factor pathway.
|
Academic Article
|
Other paradigms: better treatments are identified by better trials: the value of randomized phase II studies.
|
Academic Article
|
Evaluating the activity of temsirolimus in neuroendocrine cancer.
|
Academic Article
|
Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation.
|
Academic Article
|
Complementary and alternative medicine among advanced cancer patients enrolled on phase I trials: a study of prognosis, quality of life, and preferences for decision making.
|
Academic Article
|
Pharmacokinetic modulation of oral etoposide by ketoconazole in patients with advanced cancer.
|
Academic Article
|
In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole.
|
Academic Article
|
A phase I study of continuous infusion cilengitide in patients with solid tumors.
|
Academic Article
|
The effect of thalidomide on the pharmacokinetics of irinotecan and metabolites in advanced solid tumor patients.
|
Academic Article
|
Prospective evaluation of body surface area as a determinant of paclitaxel pharmacokinetics and pharmacodynamics in women with solid tumors: Cancer and Leukemia Group B Study 9763.
|
Academic Article
|
What is the choice of treatment for hairy cell leukemia?
|
Academic Article
|
Flushing oral oncology drugs down the toilet.
|
Academic Article
|
A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101.
|
Academic Article
|
Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial.
|
Academic Article
|
Current dilemmas in carboplatin dosing.
|
Academic Article
|
Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer.
|
Academic Article
|
Optimising the design of phase II oncology trials: the importance of randomisation.
|
Academic Article
|
Uridine 5'-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy.
|
Academic Article
|
Bar the windows but open the door to randomization.
|
Academic Article
|
The UGT1A1*28 polymorphism correlates with erlotinib's effect on SN-38 glucuronidation.
|
Academic Article
|
A programmable and implantable pumping system for systemic chemotherapy: a performance analysis in 52 patients.
|
Academic Article
|
Durability of responses to interferon alfa-2b in advanced hairy cell leukemia.
|
Academic Article
|
Inconsistent labeling of food effect for oral agents across therapeutic areas: differences between oncology and non-oncology products.
|
Academic Article
|
Encephalopathy is the dose-limiting toxicity of intravenous hepsulfam: results of a phase I trial in patients with advanced hematological malignancies.
|
Academic Article
|
Merrill Jon Egorin, MD, 1948-2010.
|
Academic Article
|
The treatment of hairy cell leukemia: an update.
|
Academic Article
|
Randomized phase II trials: a long-term investment with promising returns.
|
Academic Article
|
Germline pharmacogenomics in oncology: decoding the patient for targeting therapy.
|
Academic Article
|
Importance of food effects for oral oncology drugs.
|
Academic Article
|
Population pharmacodynamic study of amonafide: a Cancer and Leukemia Group B study.
|
Academic Article
|
Phase I trial of a genetically engineered interleukin-2 fusion toxin (DAB486IL-2) as a 6 hour intravenous infusion in patients with hematologic malignancies.
|
Academic Article
|
Cancer chemotherapy and skin changes.
|
Academic Article
|
Therapy-related acute myeloid leukemia secondary to inhibitors of topoisomerase II: from the bedside to the target genes.
|
Academic Article
|
Pharmacodynamic-pharmacokinetic relationships and therapeutic drug monitoring.
|
Academic Article
|
Phase I and pharmacokinetic study of a new antineoplastic agent: pyrazine diazohydroxide (NSC 361456).
|
Academic Article
|
A phase I and pharmacokinetic study of the quinoxaline antitumour Agent R(+)XK469 in patients with advanced solid tumours.
|
Academic Article
|
Pharmacogenetics and pharmacogenomics of anticancer agents.
|
Academic Article
|
Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics.
|
Academic Article
|
Individualizing dosing of irinotecan.
|
Academic Article
|
Pharmacokinetic modulation of irinotecan and metabolites by cyclosporin A.
|
Academic Article
|
Etoposide combined with interferon alfa-2b: novel exploitation of established etoposide pharmacokinetics and pharmacodynamics.
|
Academic Article
|
Perceptions of cancer patients and their physicians involved in phase I trials.
|
Academic Article
|
Physician-determined patient risk of toxic effects: impact on enrollment and decision making in phase I cancer trials.
|
Academic Article
|
Phase II and pharmacodynamic studies of pyrazine diazohydroxide (NSC 361456) in patients with advanced renal and colorectal cancer.
|
Academic Article
|
Body surface area as a determinant of pharmacokinetics and drug dosing.
|
Academic Article
|
Phase 1 dose escalation study of docetaxel with filgrastim support in patients with advanced solid tumors.
|
Academic Article
|
Phase I study of an oral formulation of ZD9331 administered daily for 28 days.
|
Academic Article
|
Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159/Cancer and Leukemia Group B 9480.
|
Academic Article
|
A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital.
|
Academic Article
|
Phase I study of adozelesin administered by 24-hour continuous intravenous infusion.
|
Academic Article
|
Measuring response in a post-RECIST world: from black and white to shades of grey.
|
Academic Article
|
The role of pharmacogenetics in cancer therapeutics.
|
Academic Article
|
Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping.
|
Academic Article
|
Pharmacodynamics in cancer therapy.
|
Academic Article
|
Rapamycin: something old, something new, sometimes borrowed and now renewed.
|
Academic Article
|
Pharmacogenetic pathway analysis of irinotecan.
|
Academic Article
|
A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia.
|
Academic Article
|
Phase II study of 9-aminocamptothecin in previously treated lymphomas: results of Cancer and Leukemia Group B 9551.
|
Academic Article
|
Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial.
|
Academic Article
|
Value-based insurance design in oncology.
|
Academic Article
|
Opportunities and challenges in the development of experimental drug combinations for cancer.
|
Academic Article
|
Oncology micro-cap stocks: caveat emptor!
|
Academic Article
|
Rapid response to 2'-deoxycoformycin in advanced hairy cell leukemia after failure of interferons alpha and gamma.
|
Academic Article
|
Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea.
|
Academic Article
|
Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of Paclitaxel-induced sensory peripheral neuropathy.
|
Academic Article
|
Unsupported off-label chemotherapy in metastatic colon cancer.
|
Academic Article
|
Evaluation of food effect on pharmacokinetics of vismodegib in advanced solid tumor patients.
|
Academic Article
|
Cancer pharmacogenomics: strategies and challenges.
|
Academic Article
|
Glucuronidation by UGT1A1 is the dominant pathway of the metabolic disposition of belinostat in liver cancer patients.
|
Academic Article
|
Preclinical discovery of candidate genes to guide pharmacogenetics during phase I development: the example of the novel anticancer agent ABT-751.
|
Academic Article
|
Estimation of renal cell carcinoma treatment effects from disease progression modeling.
|
Academic Article
|
The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia: CALGB 60805 (Alliance).
|
Academic Article
|
Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer.
|
Academic Article
|
Phase I dose-escalation study of onartuzumab as a single agent and in combination with bevacizumab in patients with advanced solid malignancies.
|
Academic Article
|
Targeted therapies: redefining the primary objective of phase I oncology trials.
|
Academic Article
|
Evaluation of utility of pharmacokinetic studies in phase I trials of two oncology drugs.
|
Academic Article
|
Incorporating biomarkers into drug labeling.
|
Academic Article
|
Challenges in interpreting the evidence for genetic predictors of ototoxicity.
|
Academic Article
|
Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studies.
|
Academic Article
|
Are drug labels static or dynamic?
|
Academic Article
|
Conventional dosing of anticancer agents: precisely wrong or just inaccurate?
|
Academic Article
|
Polygenic inheritance of paclitaxel-induced sensory peripheral neuropathy driven by axon outgrowth gene sets in CALGB 40101 (Alliance).
|
Academic Article
|
Vemurafenib oral bioavailability: an insoluble problem.
|
Academic Article
|
Circadian variation in plasma 5-fluorouracil concentrations during a 24 hour constant-rate infusion.
|
Academic Article
|
A pharmacogenetic study of aldehyde oxidase I in patients treated with XK469.
|
Academic Article
|
Glucuronidation of OTS167 in Humans Is Catalyzed by UDP-Glucuronosyltransferases UGT1A1, UGT1A3, UGT1A8, and UGT1A10.
|
Academic Article
|
First-in-human, phase I study of elisidepsin (PM02734) administered as a 30-min or as a 3-hour intravenous infusion every three weeks in patients with advanced solid tumors.
|
Academic Article
|
Harmonization of Renal Function Assessment Is Needed During Early Clinical Development of Oncology Drugs.
|
Academic Article
|
Clinical validity of new genetic biomarkers of irinotecan neutropenia: an independent replication study.
|
Academic Article
|
Taking a Measured Approach to Toxicity Data in Phase I Oncology Clinical Trials.
|
Academic Article
|
Drug-Drug Interactions With Oral Antineoplastic Agents.
|
Academic Article
|
Food Effect Studies for Oncology Drug Products.
|
Academic Article
|
Phase I study of lurbinectedin, a synthetic tetrahydroisoquinoline that inhibits activated transcription, induces DNA single- and double-strand breaks, on a weekly × 2 every-3-week schedule.
|
Academic Article
|
Providing Balance in ASCO Clinical Practice Guidelines: CYP2D6 Genotyping and Tamoxifen Efficacy.
|
Academic Article
|
Kinetic-Pharmacodynamic Model of Chemotherapy-Induced Peripheral Neuropathy in Patients with Metastatic Breast Cancer Treated with Paclitaxel, Nab-Paclitaxel, or Ixabepilone: CALGB 40502 (Alliance).
|
Academic Article
|
Analyzing the clinical actionability of germline pharmacogenomic findings in oncology.
|
Academic Article
|
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy.
|
Academic Article
|
The vitamin D receptor gene as a determinant of survival in pancreatic cancer patients: Genomic analysis and experimental validation.
|
Academic Article
|
Fc-gamma receptor polymorphisms, cetuximab therapy, and overall survival in the CCTG CO.20 trial of metastatic colorectal cancer.
|
Academic Article
|
Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors.
|
Academic Article
|
Clinical and Genome-Wide Analysis of Serum Platinum Levels after Cisplatin-Based Chemotherapy.
|
Academic Article
|
Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours.
|
Academic Article
|
A Cost-Focused Alternative Cancer Medication Dispensing Strategy-"Pack Splitting".
|
Academic Article
|
Personalized Management of Chemotherapy-Induced Peripheral Neuropathy Based on a Patient Reported Outcome: CALGB 40502 (Alliance).
|
Academic Article
|
A New Liver Expression Quantitative Trait Locus Map From 1,183 Individuals Provides Evidence for Novel Expression Quantitative Trait Loci of Drug Response, Metabolic, and Sex-Biased Phenotypes.
|
Academic Article
|
Interventional Pharmacoeconomics: A Novel Mechanism for Unlocking Value.
|
Academic Article
|
Weight-Based Dosing of Pembrolizumab Every 6 Weeks in the Time of COVID-19.
|
Academic Article
|
Oncology's "Hockey Stick" Moment for the Cost of Cancer Drugs-The Climate Is About to Change.
|
Academic Article
|
Accelerated Approval of Anticancer Drugs: Lessons Learned From the Example of Olaratumab.
|
Academic Article
|
Near-Equivalence: Generating Evidence to Support Alternative Cost-Effective Treatments.
|
Academic Article
|
Negative innovation: when patents are bad for patients.
|
Academic Article
|
Pharmacokinetic Simulation Analysis of Less Frequent Nivolumab and Pembrolizumab Dosing: Pharmacoeconomic Rationale for Dose Deescalation.
|
Academic Article
|
Dose Optimization of Pembrolizumab: Less May Be More.
|
Academic Article
|
Eftozanermin alfa (ABBV-621) monotherapy in patients with previously treated solid tumors: findings of a phase 1, first-in-human study.
|
Academic Article
|
Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022.
|
Concept
|
Antineoplastic Agents, Immunological
|
Academic Article
|
Special designations and the US Food and Drug Administration's "dual mandate".
|
Academic Article
|
Optimizing the doses of cancer drugs after usual dose finding.
|
Academic Article
|
Sotorasib dosing and incremental cost ineffectiveness - implications and lessons for stakeholders.
|